ALAL
2021-03-17
Thanks
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":325786586,"tweetId":"325786586","gmtCreate":1615937756745,"gmtModify":1703495168632,"author":{"id":3573967796529092,"idStr":"3573967796529092","authorId":3573967796529092,"authorIdStr":"3573967796529092","name":"ALAL","avatar":"https://static.tigerbbs.com/875b16da8a8772902d1aaf69f6c0d98a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":37,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Thanks</p></body></html>","htmlText":"<html><head></head><body><p>Thanks</p></body></html>","text":"Thanks","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/325786586","repostId":1178891078,"repostType":4,"repost":{"id":"1178891078","kind":"news","pubTimestamp":1615909549,"share":"https://ttm.financial/m/news/1178891078?lang=&edition=full","pubTime":"2021-03-16 23:45","market":"us","language":"en","title":"3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1178891078","media":"Benzinga","summary":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on M","content":"<p><b>Roche Holding AG</b>RHHBY 0.17%acquired<b>GenMark Diagnostics, Inc</b>(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day <b>Veracyte Inc</b> VCYT 1.76%announcedit completed the acquisition of<b>Decipher Biosciences, Inc.</b></p>\n<p><b>What Happened:</b>With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.</p>\n<p>In January, <b>Exact Sciences Corporation</b> EXAS 3.64%announcedit completed its acquisition of<b>Thrive Earlier Detection Corp.</b>and got Thrive’s blood-based multi-cancer detection technology.</p>\n<p><b>Why It Matters:</b>Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.</p>\n<p>Smaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.</p>\n<p>The following three companies have developed technology that could make them sought-after acquisition targets:</p>\n<p><b>BioMark Diagnostics Inc</b>BMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.</p>\n<p>BioMark is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company announced it will collaborate with Phytronix Technologies Inc “to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,” BioMark said in a press release.</p>\n<p>The collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in 2021.</p>\n<p>BioMark’s market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.</p>\n<p><b>Biocept Inc</b>BIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC and ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.</p>\n<p>Biocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.</p>\n<p>On Feb. 16, Bioceptannounced its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens usually be deemed “quantity not sufficient.”</p>\n<p>In a pivot brought on by the pandemic, Biocept alsoannounced on Feb. 3 its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.</p>\n<p>Biocept has a market cap of $79.98 million and the company's shares are at $5.87, down 1.68% Tuesday morning.</p>\n<p><b>HTG Molecular Diagnostics Inc</b>HTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.</p>\n<p>Unlike BioMark and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.</p>\n<p>On Feb. 26, HTG Molecularannouncedits EdgeSeq technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.</p>\n<p>HTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:45 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178891078","content_text":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher Biosciences, Inc.\nWhat Happened:With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.\nIn January, Exact Sciences Corporation EXAS 3.64%announcedit completed its acquisition ofThrive Earlier Detection Corp.and got Thrive’s blood-based multi-cancer detection technology.\nWhy It Matters:Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.\nSmaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.\nThe following three companies have developed technology that could make them sought-after acquisition targets:\nBioMark Diagnostics IncBMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.\nBioMark is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company announced it will collaborate with Phytronix Technologies Inc “to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,” BioMark said in a press release.\nThe collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in 2021.\nBioMark’s market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.\nBiocept IncBIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC and ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.\nBiocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.\nOn Feb. 16, Bioceptannounced its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens usually be deemed “quantity not sufficient.”\nIn a pivot brought on by the pandemic, Biocept alsoannounced on Feb. 3 its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.\nBiocept has a market cap of $79.98 million and the company's shares are at $5.87, down 1.68% Tuesday morning.\nHTG Molecular Diagnostics IncHTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.\nUnlike BioMark and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.\nOn Feb. 26, HTG Molecularannouncedits EdgeSeq technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.\nHTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":120,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/325786586"}
精彩评论